Dapaconazole

Summary

Dapaconazole (CHEMBL4297506) is a phase-3 clinical-stage small molecule; indicated across 1 condition including tinea pedis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 4
• Chemistry: 415.2 Da · C19H15Cl2F3N2O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297506
Name	Dapaconazole
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	51001696
Molecular formula	C19H15Cl2F3N2O
Molecular weight	415.2
InChIKey	FUAHXHWSMYFWGE-UHFFFAOYSA-N

SMILES: C1=CC(=CC=C1COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)C(F)(F)F

IUPAC name: 1-[2-(2,4-dichlorophenyl)-2-[[4-(trifluoromethyl)phenyl]methoxy]ethyl]imidazole

Also known as: Dapaconazol, Dapaconazole, DAPACONAZOLE

Patent coverage: 7 distinct patent families (28 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
tinea pedis	3	MONDO:0005984	EFO:0007512

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02606383	PHASE3	WITHDRAWN	Non-inferiority Phase III Trial Comparing Dapaconazole Cream 2% With Ketoconazole Cream 2% in Patients With Tinea Pedis
NCT03320486	PHASE3	COMPLETED	Non-inferiority Trial of Dapaconazole Versus Ketoconazole
NCT02824926	PHASE2	COMPLETED	Clinical Trial Comparing BL123 Versus Ketoconazole in Patients With Tinea Pedis
NCT03359070	PHASE2	COMPLETED	Clinical Trial Comparing Dapaconazole Versus Miconazole in Patients With Tinea Cruris

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).